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Role of serum allograft inflammatory  
factor-1 (AIF-1) in Egyptian type 2  
diabetic patients
ABSTRACT
Background. Diabetes mellitus (DM) is a powerful and 
independent risk factor for cardiovascular disease. The 
atherosclerosis process in diabetes is indistinguishable 
from that of the nondiabetic population, but it begins 
earlier and is often more extensive and more severe. 
AIF-1 promotes chemotaxis, spreading and migration 
of macrophages and vascular smooth muscle cells (VS-
MCs) which suggest a role of AIF-1 in the atherosclerotic 
plaque formation. Thus, this study determines the role 
of AIF-1 in the Egyptian type 2 diabetic patients. 
Results. The level of AIF-1 was significantly higher in the 
type 2 diabetic group when compared to the control 
group (p = 0.000). In type 2 diabetic patients group, 
there was a significant positive correlation between 
CIMT and AIF-1 (r = 0.468, p = 0.000). In addition to 
the positive correlation between CIMT and AIF-1, CIMT 
in regression model analysis was significantly positive 
contributing to the outcome variable (AIF-1) (p < 0.05), 
denoting the possible role of elevated serum AIF-1 level 
in atherosclerotic process with further studies on larger 
scale needed. (Clin Diabetol 2019; 8, 6: 271–276)
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Introduction 
Diabetes mellitus (DM) is a powerful and independ-
ent risk factor for cardiovascular disease which remains 
to be the major cause of death in type 2 diabetic pa-
tients [1, 2]. Low grade inflammation and activation of 
the immune system play a role in the common patho-
genesis of both insulin resistance and endothelial dys-
function and subsequently the development of type 2 
diabetes and atherosclerosis [2–4]. 
Subclinical vascular disease in type 2 diabetic pa-
tients was proved to be assessed by carotid intima me-
dia thickness (CIMT) [5–7] and the presence of plaques 
(calcified or not) [8] specially in patients with normal 
renal function by many researches. The dyslipidemic 
lipid profile (increased LDL and total cholesterol) usually 
associated with type 2 diabetes and adds more impact 
to the process of atherosclerosis process development 
in these patients [9–11].
AIF-1 (ionized calcium-binding adaptor molecule-1 
(Iba1) is a 17 kDa conserved structural cytoplasmic, 
calcium-binding, inflammation-responsive scaffold 
protein [12, 13]. It is one of the EF hand proteins’ family 
[14, 15]. 
AIF-1 was originally identified in rat cardiac al-
lografts with chronic rejection. In humans, AIF-1 is 
involved in many pathological processes where it has 
been found to be expressed by activated T cells, vas-
cular endothelial cells and blood vessel smooth muscle 
cells after a balloon injury ie: vascular trauma inducible 
cytokine [16, 17]. Thus AIF-1 may play a role in endothe-
lial dysfunction, macrophages and VSMCs activation, 
migration, reorganization and tissue remodelling as a 
response to endothelial damage [3, 16, 18]. 
The in vivo expression of AIF-1 in human VSMCs in 
atherosclerotic plaques supported the in vitro studies 
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that have shown the role of AIF-1 in atherosclerotic 
plaque formation through promotion of chemotaxis, 
cell attachment, spreading and migration of mac-
rophages and VSMCs [19].
This work aimed was to study serum AIF-1 in type 2 
diabetic patients.
Materials and methods 
One hundred subjects were included in the study 
after approval of the ethical committee of Medical Re-
search Institute and informed consents was taken. The 
included subjects were divided into two groups; Forty 
apparently healthy volunteers as a control group (group 
1), sixty type 2 diabetic patients (group 2). Subjects with 
obesity, urinary tract infections UTI and renal impair-
ment or increased urinary proteins were excluded. The 
source of finance was supplied by authors. 
To all studied subjects; thorough history taking 
was done including history of cardiovascular diseases, 
smoking habits, drinking habits, medications such as 
anti-diabetic, anti-hypertensive and anti-hyperlipemic 
drugs. Complete physical examination with special 
stress on BMI calculation, cardiovascular examination 
and measuring the carotid intima media thickness 
(CIMT) and presence of plaques (calcified or not) using 
a b mode ultrasound. 
The following laboratory investigations were done 
to all participating subjects: quantitation of urinary 
albumin, urinary proteins, creatinine, calculation of 
urinary albumin and protein to creatinine ratio, estima-
tion of serum fasting and postprandial glucose, urea, 
creatinine, calculation of estimated glomerular filtration 
rate (eGFR) [20], urine cultures and determination of 
hemoglobin A1c [21]. In addition to estimation of serum 
lipid profile (total cholesterol (TC), high density lipopro-
tein cholesterol (HDL-C), triglycerides with calculation 
of low density lipoprotein cholesterol (LDL-C). Also, 
serum C-reactive protein (CRP) [22] was estimated and 
serum AIF-1 by ELISA technique (Biocompare, South San 
Francisco, USA, catalog no. SEC288Hu) [23].
Data analysis was performed by using SPSS for Win-
dows, version 20 (Statistical Package of social sciences, 
Chicago, USA) [24]. Normality of the quantitative vari-
ables was determined with the use of the Kolmogrov-
-Smirnov test. Where normally distributed data were 
presented as mean ± standard deviation and unpaired 
Student’s t-test was used to compare a variable across 
two subgroups in addition to Pearson’s correlation test 
was used to investigate the relationship between differ-
ent quantitative variables. The non-normal distributed 
data were presented as median (minimum–maximum). 
Non parametric Mann-Whitney test was used to com-
pare the variables across two groups. Stepwise multiple 
regression analysis was conducted to test the variables 
contributing in the AIF-1 marker.
Results
Blood pressure, CIMT and presence of plaques and 
calcification in type 2 diabetic patients was significantly 
increased comparing to controls (p = 0.004, p = 0.000, 
p = 0.013) respectively (Table 1).
Glycemic control measures showed significant 
increase in fasting, post prandial blood glucose and 
HbA1c in type 2 diabetic patients than controls (p = 
0.000, p = 0.000, p = 0.000) respectively (Table 2).
Table 1. Statistical significance of clinical data of the 
studied groups
Item Group 1  
(n = 40)
Group 2  
(n = 60)
Age (years)
Mean 46.15 56.87
SD ± 8.41 ± 8.00
p 0.000**
Sex
Males 19 (47.50%) 25 (41.79%)
Females 21 (52.50%) 35 (58.30%)
p 0,794
Weight [kg]
Mean 68.15 74.62
SD ± 4.38 ± 5.45
p 0.000**
Height [m]
Mean 1.71 1.75
SD ± 0.05 ± 0.04
p 0.001*
BMI [kg/m2]
Mean 23.36 24.38
SD ± 1.39 ± 0.75
p 0.000**
Hypertension
Yes 0 (0%) 19 (31.7%)
No 20 (100%) 41 (68.3)
p 0.004*
CIMT [mm]
Mean 0.285 1.235
SD ± 0.12 ± 0.32
p 0.000**
Plaques and calcification
Yes 0 (0%) 15 (25%)
No 20 (100%) 45 (75%)
p 0.013*
c2, Chi square test, Mann-Whitney test; p — p value for comparing  
between the two groups; *statistically significant at p ≤ 0.05
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Table 2. Statistical significance of laboratory data in the 
studied groups
Item Group 1  
(n = 40)
Group 2  
(n = 60)
Total cholesterol [mg/dL]
Mean 152.85 189.25
SD ± 11.27 ± 51.53
p 0.003*
HDL-C [mg/dL]
Mean 51.05 37.55
SD ± 6.70 ± 9.71
p 0.000**
TG [mg/dL]
Mean 80.05 128.8
SD ± 25.81 ± 47.29
p 0.000**
LDL-C [mg/dL]
Mean 85.79 125.94
SD ± 10.38 ± 43.83
p 0.000**
CRP [mg/L]
Median 3.00 10.00
Min–Max (2.00–4.50) (2.00–650.00)
p 0.000**
Fasting serum glucose [mg/dL]
Mean 87.35 203.53
SD ± 9.4 ± 72.13
p 0.000**
Postprandial serum glucose [mg/dL]
Mean 108.15 190.025
SD ± 15.39 ± 76.33
p 0.000**
HbA1c (%)
Mean 4.63 7.93
SD ± 0.37 ± 2.49
p 0.000**
Serum urea [mg/dL]
Mean 27.6 29.47
SD ± 6.83 ± 7.32
p 0.336
Serum creatinine [mg/dL]
Mean 0.78 0.78
SD ± 0.14 ± 0.11
p 0.957
eGFR [ml/min]
Median 103.5 98.6
Min–Max (91.70–134.7) (90.10–157.60)
p 0.065
Urine protein/creatinine ratio [mg/g]
Mean 100.5 110.93
SD ± 23.74 ± 25.17
p 0.108
Urine albumin/creatinine ratio [mg/g]
Mean 20.25 22.67
SD ± 4.13 ± 4.6
p 0.04*
Serum AIF1 [pg/mL]
Median 90.00 1.235
Min–Max (20.00–500.00) ± 0.32
p 0.000**
c2, Chi square test, Mann-Whitney test; p — p value for comparing  
between the two groups; *statistically significant at p ≤ 0.05
Table 3. Statistical significant correlations between the 
studied parameters in the type2 diabetic group (group 2)
Item Correlation  
coefficient (r)
Significance 
(p-value)
AIF-1 and creatinine 0.338 0.008
AIF-1 and CIMT 0.468 0.000
BMI and HbA1c 0.343 0.007
BMI and fasting serum 
glucose
0.376 0.003
HbA1c and CIMT 0.257 0.047
Figure 1. Box plot illustrates the median and range of serum 
AIF-1 readings [pg/mL] among the studied groups. Box plot 
represents the interquartile range 25th–75th percentile. The 
wiskers below and above represents 10–90 percentile. The 
line across each box represents the median value. Significant 
increase in AIF-1 in the group of diabetic atherosclerotic 
patients when compared to the control group (p = 0.000)
CasesControls
.00
500.00
1000.00
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Lipid profile and CRP levels showed significant 
increase in cholesterol, triglycerides, LDL and CRP 
in type 2 diabetic patients than control (p = 0.003, 
p = 0.000, p = 0.000, p = 0.000) respectively 
(Table 2).
Renal functions tests showed only a significant in-
crease in albumin creatinine ratio in the type 2 diabetic 
patients than controls (p = 0.04) (Table 2).
AIF-1 showed significant increase in type 2 dia-
betic patients than control group (p = 0.000) (Table 2, 
Figure 1).
Pearson’s correlation test showed positive sig-
nificant correlations only between AIF-1 and creati-
nine level in addition to CIMT (r = 0.3380, r = 0.468) 
(p = 0.008, p = 0.000) respectively in type 2 diabetic 
patients (Table 3). 
Multiple regression analysis showed the over-
all model was statistically significant (F = 3.309, 
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p = 0.001). Where, CIMT was significantly positive 
contributing to the outcome variable (AIF-1) (p < 0.05), 
while other predictors were not significantly contribut-
ing to the outcome (p > 0.05) (Table 4).
Discussion
Diabetes when accompanied by other major cardio-
vascular risk factors, such as hypertension, dyslipidemia, 
and smoking, show marked increase in the incidence of 
atherosclerosis. The atherosclerosis process begins earlier 
and more aggressive in diabetes and indistinguishable 
from nondiabetic population [2]. The atherogenic lipid 
profile characterized by elevated triglycerides and low 
levels of high-density lipoprotein (HDL) cholesterol are 
major modifiable risk factors contributing to progressive 
cardiovascular risk generally in addition to both type 2 
diabetes and metabolic syndrome [25, 26].
Atherosclerosis is known to be an inflammatory 
disease as an overall process where inflammatory cells 
(pro-inflammatory cytokines secreting cells) such as 
neutrophils, lymphocytes and monocytes participate 
in the overall process of atheroscelerosis [27].
AIF-1 plays a role in endothelial cell, macrophage, 
T-lymphocyte, and VSMC activation, proliferation and 
migration which are known to play a role in inflam-
mation [3, 16, 18].
It has been shown that serum AIF-1 was increased 
in patients with diabetic nephropathy [23], also it is 
considered as a human adipokine produced mainly by 
macrophages within the white adipose tissue in obese 
patients and might participate in the regulation of adi-
pose tissue inflammation and, in turn, insulin resistance 
[28]. In the present study, all the studied groups were 
of normal e GFR and BMI. 
The level of AIF-1 was significantly higher in type 2 
diabetic groups when compared to the control group 
(p = 0.000) (Figure 1). The statistical correlation in our 
study revealed that there was a significant positive cor-
relation between CIMT and AIF-1 (r = 0.468, p = 0.000) 
in type 2 diabetic patients group, denoting the possible 
role of elevated serum AIF-1 level in atherosclerotic pro-
cess. In addition the significant increase in the presence 
of plaques and calcification in the patients than controls 
(p = 0.013) has been seen. Although there is significant 
increase in dyslipidemic profile of type 2 diabetic pa-
tients  than controls (cholesterol, triglycerides and LDL 
(p = 0.003, p = 0.000, p = 0.000) which add to the 
process of atherosclerosis development in these patients, 
there were no significant correlations between dyslipi-
demia and AIF-1 level in these patients thus a study on 
larger scale of type 2 diabetic patients is needed. 
In multiple linear regression analysis, the overall 
model is statistically significant (F = 3.309, p = 0.001) 
and it is found that increased CIMT is significantly con-
tributing to elevated serum AIF-1 level in type 2 diabetic 
patients (p < 0.05). Thus, elevated serum AIF-1 level in 
type 2 diabetic patients in addition to its positive sig-
nificant correlation with CIMT add to the possible role 
of AIF1 in contribution to the process of atherosclerotic 
changes in type 2 diabetic patients. This was consis-
tent with Berglund et al., 2012 [29] who stated that 
expression of AIF-1 mRNA in human carotid plaques 
Table 4. Multiple regression analysis
Model Regression  
coefficients
t Sig. 95% confidence  
interval for B
B S.E Lower bound Upper bound
(Constant) 1235.852 1068.189 1.157 0.251 –895.687 3367.39
Age –6.52 5.094 –1.191 0.280 –16.687 3.648
BMI –10.074 40.213 –0.251 0.803 –90.318 70.170
Hypertension –139.901 94.727 –1.477 0.144 –328.554 49.124
Plaques and calcification 68.936 115.962 0.594 0.554 –162.462 300.334
CIMT 502.386 127.204 3.949 0.001* 248.554 756.217
Fasting blood sugar –0.449 0.746 –0.602 0.549 –1.939 1.040
Post prandial blood sugar 0.118 0.703 0.168 0.867 –1.284 1.520
Albumin to creatinine ratio 0.467 0.897 0.134 0.890 –2.284 3.652
HbA1c –20.978 33.729 –0.622 0.536 –88.340 46.383
Cholesterol 0.421 1.264 0.333 0.740 –2.102 2.945
LDL 0.169 1.224 –1.581 0.138 –2.273 2.611
Triglycerides –0.185 1.286 –0.144 0.886 –2.753 2.383
CRP –0.353 0.479 –0.078 0.464 –1.640 0.603
e-GFR –6.404 3.486 –1.837 0.071 –13.361 0.552
*Predictors are significantly contributing to the outcome variable if p < 0.05
Mona Kamal ElDeeb et al., Role of serum allograft inflammatory factor-1 (AIF-1) in Egyptian type 2 diabetic patients
275
associates with less extracellular matrix and a more 
pro-inflammatory plaque and plasma profile, features 
that may predispose to plaque rupture.
Zhao et al, 2013 [14] reported that AIF-1 is ex-
pressed by activated lipid-rich macrophages and VSMCs 
during the progression of atherosclerosis. In this regard, 
AIF-1 may be involved in the early stage of atheroscle-
rosis and CAD. Kelemen et al, in 2005 [30] stated that 
increased AIF-1 expressed in activated T lymphocytes 
enhance activation of adjacent arterial vascular smooth 
muscle cells (VSMCs) and development of athero-
sclerosis. Expression of AIF-1 seems to be involved in 
vascular smooth muscle cells and macrophages migra-
tion, chemotaxis, proliferation and tissue remodeling 
as a response to endothelial damage which suggest 
a positive role of AIF-1 in the atherosclerotic plaque 
formation. These in vitro studies were supported by 
immunohistochemical analysis which has shown in vivo 
protein expression of AIF-1 in human smooth muscle 
cells in atherosclerotic plaques [19].
In the present work, by drawing receiver operating 
characteristic (ROC) curve of serum AIF-1 at a cutoff 
value of 120 pg/mL in the studied group (Figure 2), 
the area under the curve (AUC) for AIF-1 was 0.843, 
p ≤ 0.0001. The sensitivity, specificity, positive predictive 
value, negative predictive value and overall accuracy 
of AIF-1 for detection of atherosclerosis were 98.33%, 
70%, 91%, 93% and 91% respectively. Thus, the present 
study supported that AIF-1 can be a helpful marker for 
early detection of atherosclerosis and prediction of 
cardiovascular complications in type 2 diabetic patients.
Conclusion
In conclusion, AIF-1 was significantly higher in the 
type 2 diabetic patient group (group 2) when compared 
to the control group (group 1). In the group of type 2 
diabetic patients AIF-1 showed positive correlation with 
CIMT denoting the possible relation between increased 
AIF-1 levels and subsequent vascular damage and the 
process of atherosclerosis in type 2 diabetes.
Recommendations: further work is needed on a 
larger number of type 2 diabetic patients with higher 
focus on the presence of vascular calcification and 
atherosclerosis. 
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